Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.

The Queen of Spain attended the opera alongside husband King Felipe in Bilbao, northern Spain.

As Christmas approaches, so too does a fresh batch of box sets and greatest hits packages. Could there be something for the music lover in your life? The Mail's music critic has a listen ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

From glittering galas to red carpet premieres, the world's royals have mastered the art of making an entrance - and their footwear often steals the show. Whether it's a dazzling pair of ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

$1.85B Expansion in Johnston County Doubling Workforce of 700 Collaborative Success for EDPNC, NCBiotech and State/Local Officials Each Biomanufacturing Job Creates Six Total Jobs Novo Nordisk, a key ...

After hours: November 29 at 4:58 p.m. EST ...

After hours: 29 November at 16:58 GMT-5 ...